The results of this study support the hypothesis that TP53 may be a valuable biomarker that can identify metastatic gastric cancer patients with the greatest benefit from an anti-angiogenic, anti-VEGFR2 systemic therapy. This evidence concerns the gene TP53 and gastric cancer.